UBS AM
IMNM icon

UBS AM’s Immunome IMNM Stock Holding History

UBS AM’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.09M Buy
187,011
+63,262
+51% +$1.41M ﹤0.01% 1667
2025
Q4 		$2.66M Buy
123,749
+11,451
+10% +$201K ﹤0.01% 1761
2025
Q3 		$1.32M Sell
112,298
-74,400
-40% -$740K ﹤0.01% 1910
2025
Q2 		$1.74M Buy
186,698
+108,354
+138% +$888K ﹤0.01% 2204
2025
Q1 		$527K Buy
78,344
+20,151
+35% +$193K ﹤0.01% 2493
2024
Q4 		$618K Buy
58,193
+14,328
+33% +$173K ﹤0.01% 2516
2024
Q3 		$641K Sell
43,865
-8,189
-16% -$116K ﹤0.01% 2577
2024
Q2 		$630K Buy
52,054
+40,354
+345% +$631K ﹤0.01% 2561
2024
Q1 		$289K Buy
+11,700
New +$237K ﹤0.01% 2406

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

UBS AM's IMNM Position: Q1 2026 in Review

UBS AM increased its Immunome (IMNM) stake by 51% in Q1 2026, buying an estimated $1.41M and bringing the position to 187,011 shares worth $4.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1667.

UBS AM first reported a position in IMNM in Q1 2024 and has held it in 9 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • UBS AM held 187,011 shares of Immunome worth $4.09M as of Q1 2026.
  • UBS AM bought 63,262 Immunome shares in Q1 2026, an estimated $1.41M.
  • Immunome made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1667 holding.
  • UBS AM first reported a position in Immunome in Q1 2024 and has held it in 9 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.